-
公开(公告)号：EP2374804A1
公开(公告)日：2011-10-12
申请号：EP11160853.5
申请日：2004-04-22
Applicant: Genzyme Corporation
Inventor： Bridger, Gary, J. , McEachern, Ernest, J. , Skerlj, Renato , Schols, Dominique , Skupinska, Krystyna , Chen, Gang , Zhu, Yongbao , Harwig, Curtis , Kaller, Al , Baird, Ian , Metz, Markus
IPC: C07D401/04 , A61K31/40 , A61K31/445 , A61K31/495 , A61K31/54 , A61K31/55 , C07D223/02 , C07D227/00
CPC classification number: C07D401/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: Compounds that interact with the CXCR4 receptor are described. The compounds are useful in treating for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.
Abstract translation: 描述了与CXCR4受体相互作用的化合物。 该化合物可用于治疗实例，HIV感染和炎性病症如类风湿性关节炎，以及哮喘或癌症，并且可用于提高祖细胞和干细胞计数的方法以及升高白细胞计数的方法。
-
公开(公告)号：EP1401821A1
公开(公告)日：2004-03-31
申请号：EP02741451.5
申请日：2002-06-11
Applicant: SK Corporation
Inventor： CHOI, Yong-Moon , KIM, Yong-Kil , PARK, Chun-Eung , LEE, Eun-Ho
IPC: C07D295/108 , C07D241/04 , C07D223/02 , C07D211/06 , C07D207/04
CPC classification number: C07D207/404 , C07D211/14 , C07D211/22 , C07D211/32 , C07D217/04 , C07D295/13 , C07D409/12
Abstract: The present invention relates to novel 1,2- or 1,3-diamine and amide compounds and pharmaceutically useful salts thereof and methods for treating central nervous system diseases. The present 1,2- or 1,3-diamine and amide compounds have high binding affinity to the sigma receptor.
Abstract translation: 本发明涉及新的1,2-或1,3-二胺和酰胺化合物及其药学上有用的盐和治疗中枢神经系统疾病的方法。 本发明的1,2-或1,3-二胺和酰胺化合物对σ受体具有高结合亲和力。
-
公开(公告)号：EP0460023A4
公开(公告)日：1992-04-08
申请号：EP90903669
申请日：1990-02-07
Applicant: ABBOTT LABORATORIES
Inventor： BROOKS, DEE, W. , BASHA, ANWER
IPC: C07D487/04 , C07D223/02 , A61K31/505 , A61K31/54 , C07D227/02 , C07D265/30 , C07D475/08 , C07D475/10
CPC classification number: C07D487/04
-
公开(公告)号：EP1756063B1
公开(公告)日：2015-07-08
申请号：EP05745656.8
申请日：2005-05-04
Applicant: Incyte Corporation
Inventor： YAO, Wenqing , ZHUO, Jincong , XU, Meizhong , ZHANG, Colin , METCALF, Brian , HE, Chunhong , QIAN, Ding-Quan
IPC: C07D221/00 , C07D223/02 , C07D223/04 , C07D231/04
CPC classification number: C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
-
公开(公告)号：EP0656356A1
公开(公告)日：1995-06-07
申请号：EP93919555.8
申请日：1993-08-18
Applicant: JAPAN TOBACCO INC.
Inventor： SHIBATA, Saizo, Pharmaceutical Research Labor. of , YAMADA, Yasuki, Pharmaceutical Research Labor. of , ANDO, Koji, Pharmaceutical Research Labor. of , FUKUI, Kiyoshi, Toxicology Research Labor. of , NAKAMURA, Ikuro, Yoshitomi Pharmaceutical Ind. Ltd , UCHIDA, Itsuo, Pharmaceutical Research Labor. of
IPC: C07D317/28 , C07D405/12 , C07D263/04 , C07D319/06 , C07D215/26 , C07D223/02 , C07C225/14 , C07C271/16 , C07C271/18 , A61K31/335 , C07C233/63 , C07C217/18 , C07D295/20
CPC classification number: C07D295/205 , A61K38/00 , C07C233/63 , C07C271/16 , C07C271/18 , C07C275/24 , C07C2601/14 , C07D295/20 , C07D295/215 , C07D317/28 , C07D405/12 , C07D405/14 , C07D417/12 , C07D491/10 , C07F7/1852 , C07F7/1856 , C07K5/06078 , C07K5/06139
Abstract: A dioxacycloalkane compound represented by general formula [1], a pharmaceutically acceptable salt thereof, an intermediate for producing the compound, and a process for producing the intermediate. The compound [1] has a potent activity of inhibiting renin and a persistent hypotensive effect by peroral administration, thus being useful as a hypotensive and a remedy for cardiac insufficiency. General formula [1] wherein A represents [a] or [b]; W represents [c], [d] or [e], X represents -CO- or -SO₂-; Y represents -CH₂, -O- or -NR²⁵-; R¹ represents aralkyl which may be substituted by lower alkoxy; R² represents hydrogen or lower alkyl; R³ represents -(CH₂) d -SR²⁶ or [f]; R⁴ and R⁵ represent each hydrogen or lower alkyl; and E represents -C(R²⁹)(R³⁰)- or -CH₂CH₂-.
Abstract translation: 由通式[1]表示的二氧杂环烷烃化合物，其药学上可接受的盐，用于制备该化合物的中间体以及用于生产该中间体的方法。 化合物[1]具有抑制肾素的有效活性和通过口服给药持续的降血压作用，因此可用作降压药和心功能不全的治疗药。 通式[1]其中A代表[a]或[b]; W代表[c]，[d]或[e]，X代表-CO-或-SO 2 - ; Y代表-CH 2，-O-或-NR 25 - ; R 1代表可以被低级烷氧基取代的芳烷基; R 2代表氢或低级烷基; R 3代表 - （CH 2）d-SR 20或[f]; R 4和R 5分别表示氢或低级烷基; E代表-C（R 20）（R 36） - 或-CH 2 CH 2 - 。
-
Patent Agency Ranking
公开(公告)号：EP0226196A3
公开(公告)日：1988-10-05
申请号：EP86117347
申请日：1986-12-12
Inventor： FISCHER, ULF, DR. , SCHNEIDER, FERNAND, DR. , WIDMER, ULRICH, DR.
IPC: C07D237/00 , A61K20060101 , A61K31/38 , A61K31/395 , A61K31/44 , A61K31/495 , A61K31/50 , A61K31/535 , A61P21/02 , A61P25/08 , A61P25/20 , C07D20060101 , C07D221/00 , C07D223/02 , C07D237/26 , C07D257/00 , C07D333/00 , C07D471/00 , C07D471/04 , C07D495/00 , C07D495/04 , C07D495/06 , C07D495/08 , C07D495/14 , C07D513/00 , C07D513/02 , C07D513/04 , C07D513/06 , C07D513/08 , C07D513/12 , C07D513/14 , C07D513/16 , C07D513/18 , C07D513/20 , C07D513/22 , C07D519/00
CPC classification number: C07D471/04 , C07D495/14 , C07D513/04 , C07D513/14
-
公开(公告)号：EP1756063A4
公开(公告)日：2009-03-25
申请号：EP05745656
申请日：2005-05-04
Applicant: INCYTE CORP
Inventor： YAO WENQING , ZHUO JINCONG , XU MEIZHONG , ZHANG COLIN , METCALF BRIAN , HE CHUNHONG , QIAN DING-QUAN
IPC: C07D221/00 , A61K31/401 , A61K31/445 , C07D207/06 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/263 , C07D207/30 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D223/02 , C07D223/04 , C07D231/04 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
CPC classification number: C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
Abstract: The present invention relates to inhibitors of 11-ß hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-ß hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
-
公开(公告)号：EP1704142A4
公开(公告)日：2008-08-20
申请号：EP04815989
申请日：2004-12-28
Applicant: TAIGEN BIOTECHNOLOGY CO LTD
Inventor： YANG SYAULAN , WU JEN-DAR , SU FENG-YIH , KUO CHUN-WEI , CHEN WEN-CHANG , XIANG YIBIN , WANG CHING-CHENG , LIAO SHAO-YING
IPC: C07D207/06 , A61K31/4015 , A61K31/675 , A61K38/04 , A61P31/12 , C07D207/04 , C07D207/26 , C07D223/02 , C07D405/06
CPC classification number: C07D207/26 , A61K31/4015 , A61K31/675 , A61K38/04 , C07D405/06
-
9.发明公开
公开(公告)号：EP1615633A4
公开(公告)日：2008-07-09
申请号：EP04760161
申请日：2004-04-22
Applicant: ANORMED INC
Inventor： BRIDGER GARY J , MCEACHERN ERNEST J , SKERLJ RENATO , SCHOLS DOMINIQUE , SKUPINSKA KRYSTYNA , CHEN GANG , ZHU YONGBAO , HARWIG CURTIS , KALLER AL , BAIRD IAN , METZ MARKUS
IPC: C07D401/04 , A61K20060101 , A61K31/40 , A61K31/444 , A61K31/445 , A61K31/495 , A61K31/54 , A61K31/55 , C07D223/02 , C07D227/00 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D409/14 , C07D413/14 , C07D417/14
-
10.发明公开AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS 有权AMIDOVERBINDUNGEN UND DEREN VERWENDUNG ALS PHARMAZEUTIKA
公开(公告)号：EP1756063A1
公开(公告)日：2007-02-28
申请号：EP05745656.8
申请日：2005-05-04
Applicant: INCYTE CORPORATION
Inventor： YAO, Wenqing , ZHUO, Jincong , XU, Meizhong , ZHANG, Colin , METCALF, Brian , HE, Chunhong , QIAN, Ding-Quan
IPC: C07D221/00 , C07D223/02 , C07D223/04 , C07D231/04
CPC classification number: C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
Abstract: The present invention relates to inhibitors of 11-ß hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-ß hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
Abstract translation: 本发明涉及11型羟基类固醇脱氢酶1型抑制剂，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-²羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病的表达或活性相关的各种疾病。
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.015 seconds)
